A Multicenter Study to Clarify the Optimal HCV-RNA Negative Period during Combined Therapy with Pegylated Interferon Plus Ribavirin in Patients with Chronic Hepatitis Caused by HCV Genotype 2

スポンサーリンク

概要

• 論文の詳細を見る

• Objective A multicenter open trial was performed to clarify the optimal duration of combined pegylated interferon (Peg-IFN) plus ribavirin therapy in patients with chronic hepatitis caused by HCV genotype 2. Methods A total of 100 patients seen between 2005 and 2007 received the combination therapy for 4 to 52 weeks. The cutoff value of the HCV-RNA-negative (titers under 1.7 Log IU/mL) period during the therapy to predict sustained virological response (SVR) was determined by ROC curve and multivariate logistic regression analyses. The result was validated in 48 patients between 2008 and 2009. Results SVR was achieved in 78 patients. Serum HCV-RNA titers decreased to less than 1.7 Log IU/mL at 4 weeks of the therapy in 60 patients. The SVR rate in these patients was 85%, which was significantly higher than that of remaining 40 patients with a SVR rate of 68%. An HCV-RNA-negative period of ≥17 weeks was selected as the cutoff value, which showed a significant odds ratio of 4.77 for SVR. Among the 35 patients who showed a decrease of the serum HCV-RNA of less than 1.7 Log IU/mL between 8 and 16 weeks of therapy, the SVR rate was significantly higher in 16 patients with a serum HCV-RNA-negative period of ≥17 weeks (94%) than in 19 patients in whom the period was less than 17 weeks (63%). Similar results were obtained in the subsequent validation study. Conclusion Prolonged combined Peg-IFN plus ribavirin therapy, with an HCV-RNA-negative period of ≥17 weeks, yielded good therapeutic outcomes in patients with chronic HCV genotype 2 hepatitis.

著者

• YOSHIDA Takeshi

  Saitama Social Insurance Hospital

• Mochida Satoshi

  Department Of Applied Chemistry Faculty Of Engineering Osaka University

• Matsui Atsushi

  Shisei Hospital, Japan

• Yoshida Takeshi

  Saitama Social Insurance Hospital, Japan

• Nagoshi Sumiko

  Department of Gastroenterology & Hepatology, Saitama Medical University, Japan

• Nakamura Ikuo

  Saitama Medical Center, Jichi Medical University, Japan

• Takegoshi So

  Asakadai Central General Hospital, Japan

• Fujiwara Kenji

  Japan Labour Health and Welfare Organization, Yokohama Rosai Hospital, Japan

• Harada Youji

  Toda Chuo General Hospital, Japan

• Sekine Chuichi

  Saiseikai Kawaguchi General Hospital, Japan

• Koshima Yohei

  Saitama Red Cross Hospital, Japan

• Funyu Junji

  Chichibu Hospital, Japan

• Nishikawa Ko

  Ageo Central General Hospital, Japan

• Sotome Naoki

  Kumagaya General Hospital, Japan

• Toshima Kenichi

  Musashiranzan Hospital, Japan

• Shiomi Masao

  Shiomi Hospital, Japan

• Tanaka Masahiko

  Kanetsu Hospital, Japan

• Saito Akira

  Nishisaitama-chuo National Hospital, Japan

関連論文

• Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C
• Indication criteria for liver transplantation for acute liver failure in Japan
• Rhodium-catalyzed Oxidative Coupling/Cyclization of Benzamides with Alkynes via C-H Bond Cleavage
• Sex- or gender-specific medicine in hepatology
• Novel classification of acute liver failure through clustering using a self-organizing map : usefulness for prediction of the outcome
• Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma
• The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome : a multicenter, open-label, explorative study
• Algorithm to determine the outcome of patients with acute liver failure : a data-mining analysis using decision trees
• A Multicenter Study to Clarify the Optimal HCV-RNA Negative Period during Combined Therapy with Pegylated Interferon Plus Ribavirin in Patients with Chronic Hepatitis Caused by HCV Genotype 2
• Acute liver failure in Japan : definition, classification, and prediction of the outcome
• Diagnostic criteria of acute liver failure : A report by the Intractable Hepato-Biliary Diseases Study Group of Japan
• Novel scoring system as a useful model to predict the outcome of patients with acute liver failure : Application to indication criteria for liver transplantation

もっと見る 閉じる

スポンサーリンク